

Special Issue

Recent Insights of Antibody-Drug Conjugate Effectiveness

Message from the Guest Editors

Antibody–drug conjugates (ADCs) are a new type of anti-cancer drug designed to deliver cytotoxic payloads specifically to cancer cells. Nine ADCs have received approval from the U.S. Food and Drug Administration so far, and over 100 ADCs are being investigated in nearly 600 clinical trials currently. In this Special Issue of *Pharmaceuticals*, we review the current stage of ADC development. We discuss the payloads used in ADCs, the conjugation and linker chemistry, and the clinical applications. We also discuss the limitations of ADC technology, drug resistance to ADCs, and possible strategies to improve the efficacy of these anti-cancer drugs and to decrease their side effects.

Guest Editors

Dr. Jeffrey V. Leyton

Department of Nuclear Medicine and Radiobiology Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada

Dr. Mark Barok

1. Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
2. Laboratory of Molecular Oncology, Biomedicum, University of Helsinki, Helsinki, Finland

Deadline for manuscript submissions

closed (5 March 2022)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 6.1
Indexed in PubMed



mdpi.com/si/59824

Pharmaceuticals
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 6.1
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Pharmaceutical Science)